Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4985987 | 0.92 | KDM4E (0.44) | FAAHKDM4EALDH1A1GAALMNA | |
| SCHEMBL4986723 | 0.89 | KDM4E (0.46) | FAAHKDM4EALDH1A1GAALMNA | |
| SCHEMBL4993429 | 0.88 | DRD4 (0.42) | GRM2 | |
| SCHEMBL4985028 | 0.85 | KDM4E (0.45) | FAAHKDM4EALDH1A1KMT2AGRM2 | |
| SCHEMBL4985480 | 0.83 | FAAH (0.43) | FAAHKDM4EALDH1A1LMNAHTT | |
| SCHEMBL4983033 | 0.83 | GRM2 (0.41) | KDM4EALDH1A1KMT2AGRM2PARP1 | |
| SCHEMBL4988838 | 0.82 | GRM2 (0.47) | FAAHKDM4EALDH1A1KMT2AGRM2 | |
| SCHEMBL4989374 | 0.81 | HRH3 (0.43) | FAAHKMT2AMGLLLTA4H | |
| SCHEMBL4986167 | 0.80 | GRM2 (0.41) | FAAHKDM4EALDH1A1LMNAHTT | |
| SCHEMBL4986124 | 0.80 | CLPP (0.42) | FAAHKDM4EALDH1A1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | FAAH 494/4885KDM4E 4128/4885ALDH1A1 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.